Efficacy of nicorandil in patients with sepsis-induced cardiomyopathy and its effects on prognosis
Received:October 10, 2020  
View Full Text  View/Add Comment  Download reader
DOI:10.11915/j.issn.1671-5403.2021.06.087
Key words:sepsis  cardiomyopathy  infection  nicorandil  myocardial injury This work was supported by Project of Level D Six Top Talents of Jiangsu Province
Author NameAffiliationE-mail
ZHANG Yi Intensive Care Unit, Xuzhou 221000, Jiangsu Province, China
Department of Anesthesiology,Affiliated Hospital of Xuzhou Medical University, Xuzhou 221000, Jiangsu Province, China 
zhaowj886@sina.comefficacy 
JIANG Wen Department of Anesthesiology,Affiliated Hospital of Xuzhou Medical University, Xuzhou 221000, Jiangsu Province, China zhaowj886@sina.comefficacy 
ZHAO Xue Department of Anesthesiology,Affiliated Hospital of Xuzhou Medical University, Xuzhou 221000, Jiangsu Province, China zhaowj886@sina.comefficacy 
LI Peng-Fei Department of Anesthesiology,Affiliated Hospital of Xuzhou Medical University, Xuzhou 221000, Jiangsu Province, China zhaowj886@sina.comefficacy 
ZHAO Wen-Jing Intensive Care Unit, Xuzhou 221000, Jiangsu Province, China zhaowj886@sina.comefficacy 
Hits: 460
Download times: 371
Abstract:
      Objective To explore the efficacy of nicorandil in the patients with sepsis-induced cardiomyopathy (SIC) and its effect on the prognosis. Methods A total of 80 SIC patients admitted to the Intensive Care Unit of the Affiliated Hospital of Xuzhou Medical University from May 2019 to March 2020 were selected and randomly divided into control group and nicorandil group, with 40 in each group. Both groups were given standard anti-septic treatment. Nicoranolil group were given additional nicorandil injection. All patients were treated for consecutive 7 days. Cardiac function and markers of myocardial injury were assessed before and after treatment. Sequential organ failure assessment (SOFA) and changes in acute physiology and chronic health evaluation system Ⅱ (APACHE Ⅱ) were observed before and after treatment. SPSS statistics 22.0 was used for data analysis. Inter-group and intra-group comparison was made using t-test, Mann-Whitney U test and χ2 test. Results After treatment, patients in nicorandil group were found to be better than patients in control group in cardiac function, myocardial injury markers,SOFA and APACHE Ⅱ, with statistically significant difference (all P<0.05). The number of adverse cardiac events during hospitalization and the incidence of severe arrhythmia were significantly decreased in nicorandial group (all P<0.05). Conclusion Compared with standard treatment, nicorandil can reduce myocardial damage in the SIC patients, improve their cardiac function, stabilize the condition, and enhance the prognosis.
Close